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Clinical Utility of Random Anti–Tumor Necrosis Factor
Drug–Level Testing and Measurement of Antidrug Antibodies
on the Long-Term Treatment Response in
Rheumatoid Arthritis
Meghna Jani,1 Hector Chinoy,2 Richard B. Warren,3 Christopher E. M. Griffiths,3
Darren Plant,4 Bo Fu,5 Ann W. Morgan,6 Anthony G. Wilson,7 John D. Isaacs,8
Kimme L. Hyrich,9 and Anne Barton,4 on behalf of the Biologics in Rheumatoid Arthritis
Genetics and Genomics Study Syndicate Collaborators
Objective. To investigate whether antidrug anti-
bodies and/or drug non-trough levels predict the long-
term treatment response in a large cohort of patients
with rheumatoid arthritis (RA) treated with adalimu-
mab or etanercept and to identify factors influencing
antidrug antibody and drug levels to optimize future
treatment decisions.
Methods. A total of 331 patients from an observa-
tional prospective cohort were selected (160 patients
treated with adalimumab and 171 treated with etanercept).
Antidrug antibody levels were measured by radioimmuno-
assay, and drug levels were measured by enzyme-linked
immunosorbent assay in 835 serial serum samples
obtained 3, 6, and 12 months after initiation of therapy.
The association between antidrug antibodies and drug
non-trough levels and the treatment response (change
in the Disease Activity Score in 28 joints) was evaluated.
Results. Among patients who completed 12
months of followup, antidrug antibodies were detected in
24.8% of those receiving adalimumab (31 of 125) and in
none of those receiving etanercept. At 3 months, antidrug
antibody formation and low adalimumab levels were signi-
ficant predictors of no response according to the Euro-
pean League Against Rheumatism (EULAR) criteria at 12
months (area under the receiver operating characteristic
curve 0.71 [95% confidence interval (95% CI) 0.57, 0.85]).
Antidrug antibody–positive patients received lower
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median dosages of methotrexate compared with antidrug
antibody–negative patients (15 mg/week versus 20 mg/
week; P5 0.01) and had a longer disease duration (14.0
versus 7.7 years; P5 0.03). The adalimumab level was the
best predictor of change in the DAS28 at 12 months, after
adjustment for confounders (regression coefficient 0.060
[95% CI 0.015, 0.10], P5 0.009). Etanercept levels were
associated with the EULAR response at 12 months
(regression coefficient 0.088 [95% CI 0.019, 0.16], P 5
0.012); however, this difference was not significant after
adjustment. A body mass index of ‡30 kg/m2 and poor
adherence were associated with lower drug levels.
Conclusion. Pharmacologic testing in anti–tumor
necrosis factor–treated patients is clinically useful even
in the absence of trough levels. At 3 months, antidrug
antibodies and low adalimumab levels are significant
predictors of no response according to the EULAR cri-
teria at 12 months.
The introduction of anti–tumor necrosis factor
(anti-TNF) therapy transformed the treatment of rheu-
matoid arthritis (RA). However, up to 40% of patients
with RA fail to respond to anti-TNF treatment, because
of either primary inefficacy or loss of response (1–3).
When patients fail to have a response to their first anti-
TNF drug, therapeutic options may include switching to a
biologic agent with a different mechanism of action,
switching to an alternative anti-TNF drug, or increasing
the dose/reducing the length of time between infusions.
The choice of a second-line agent is often based on cost
and local policies as opposed to an understanding of the
mechanistic etiology of treatment failure. At present, no
biomarkers are readily available to predict which treat-
ments will work better for which patients, because until
recently, the mechanisms underlying these responses have
not received much attention (4,5). The ability to predict
nonresponse at an early stage of treatment with a biologic
agent could potentially have major implications for health
care economics and help to optimize patient care.
One explanation of the poor efficacy of anti-TNF
therapies is immunogenicity leading to the development
of antidrug antibodies and low drug levels. Previous
studies demonstrated that the presence of antibodies
against anti-TNF monoclonal antibodies reduces the
response to treatment and increases the risk of treat-
ment discontinuation (6,7). Meanwhile, the utility of
pharmacologic monitoring in clinical practice continues
to be debated (8,9). Indeed, the 2013 European League
Against Rheumatism (EULAR) Task Force recommen-
dations for the management of RA (9) included the
following questions in their research agenda: “Is measure-
ment of serum drug and/or drug antibody levels useful in
clinical practice?” and “How can immunogenicity of [bio-
logic disease-modifying antirheumatic drugs] DMARDs
explain the similarity of clinical trial data observed with
both immunogenic and non-immunogenic compounds?”
A challenge when interpreting the results of
immunogenicity studies is wide variation in the reported
antidrug antibody frequency, which may be related to
several intrinsic patient factors and drug-related and
treatment-associated factors, including concomitant treat-
ment with DMARDs (10,11). The diversity of detection
methods, timing of the sample collection, as well as the
presence of free drug may mask the detection of antidrug
antibodies due to drug interference (6,8). The latter con-
cern may be addressed by performing radioimmunoassay
(RIA), which is less susceptible to drug interference com-
pared with enzyme-linked immunosorbent assays (ELI-
SAs) (12) and has been used successfully in a clinical
setting (5,13,14).
To circumvent the issue of drug interference,
previous studies used trough-level serum samples to
measure drug concentrations and antidrug antibody lev-
els, obtained immediately prior to administration of the
patient’s next scheduled dose. For treatment with agents
such as adalimumab and etanercept, which are adminis-
tered subcutaneously by the patient at home, ascertain-
ment of trough levels would most likely require a
separate hospital visit after inefficacy of the drug has
been determined by the clinician. The practical implica-
tions for the patient and the impact on service delivery of
obtaining serum antidrug antibody trough levels and
drug levels pose additional challenges in clinical practice.
The aims of this study were, first, to investigate
whether the presence of antidrug antibodies and/or drug
non-trough levels predict treatment response in a large
cohort of RA patients treated with adalimumab or eta-
nercept and, second, to identify pretreatment factors that
may predict antidrug antibody formation and/or drug lev-
els that may help optimize future treatment decisions.
PATIENTS AND METHODS
Patients. Patients were recruited to participate in a
prospective observational cohort study, the Biologics in Rheu-
matoid Arthritis Genetics and Genomics Study Syndicate
(BRAGGSS) (15), from 60 centers across the UK between
November 2008 and March 2013 (see Appendix A for the
BRAGGSS collaborators). From the total cohort, 311 patients
were selected based on the following inclusion criteria: a diag-
nosis of RA according to the American College of Rheumatol-
ogy 1987 revised criteria for the classification of RA (16);
active disease as indicated by a Disease Activity Score in 28
joints (17) using the C-reactive protein level (DAS28-CRP) of
$5.1 despite previous treatment with at least 2 DMARDs,
including methotrexate; white (Caucasian ancestry); and
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planned initiation of treatment with either adalimumab or
etanercept. Adalimumab and etanercept were the anti-TNF
agents most commonly prescribed for the treatment of RA
in the national UK cohort at the time that this study was
designed. All patients were prescribed adalimumab 40 mg sub-
cutaneously every other week and etanercept 50 mg subcuta-
neously every week throughout the duration of the study.
At baseline and following initiation of therapy, serum
samples were collected from the patients, and disease activity
was measured at 3, 6, and 12 months. Clinician and patient
questionnaires (including self-reported adherence) were com-
pleted at each time point. For the purposes of the current
study, adherence was classified as previously defined (18).
Therapeutic response was evaluated at months 3, 6, and 12 of
anti-TNF therapy, using the EULAR response criteria (19)
and/or change in the DAS28. The latter was defined as the dif-
ference between the DAS28 after initiation of treatment and
the pretreatment DAS (i.e., baseline DAS time point 3/6/12
month DAS28). Therefore, an improvement with treatment
would equate to a positive change in the DAS28 and vice
versa. All serum samples collected were sent to the Centre for
Musculoskeletal Research for central processing, storage, and
analysis. Contributing patients provided written informed con-
sent, and the study was approved by a multicenter ethics com-
mittee (COREC 04/Q1403/37).
Measurement of antidrug antibodies against adali-
mumab or etanercept and drug levels. Serum drug levels
were tested in all serial samples after initiation of treatment
and were measured in-house using a sandwich ELISA accor-
ding to the instructions of the manufacturer (Progenika
Biopharma). The presence of antidrug antibodies against ada-
limumab and etanercept was determined by RIA (performed
by personnel at Sanquin Diagnostic Services, Amsterdam, The
Netherlands). The assay measures specific high-avidity IgG
antibodies against the drug, using an antigen-binding test, as
previously described (5,20). Compared with ELISA, RIA is
less prone to drug/rheumatoid factor (RF) interference (12),
and can detect IgG4 antibodies, which have greater neutraliza-
tion potential (21,22). All serum samples obtained from
patients receiving adalimumab were tested and defined as pos-
itive for anti-adalimumab antibodies if titers were .12 arbi-
trary units (AU)/ml; this cutoff was determined based on
previous reference serum comparisons (5). Previous studies
did not detect antibodies to etanercept using RIA (13,23,24);
however, 60 serum samples, which included samples obtained
at all time points after initiation of etanercept treatment, were
tested for completeness. Similarly, patients were defined as
being anti-etanercept antibody positive if the antibody level
was .12 AU/ml. To establish a concentration–effect curve, all
331 patients were categorized according to drug concentra-
tions (from low to high), correlating changes in the DAS28
across all time points.
Statistical analysis. Between-group comparisons were
assessed by the t-test for independent samples, the Wilcoxon-
Mann-Whitney U test, or the chi-square test, as appropriate.
Nonparametric Spearman’s correlations between the presence
of antidrug antibodies and drug levels were determined. The
generalized estimating equation (GEE) model with an identity
link for longitudinal continuous outcomes was used to test the
association between treatment response and drug and anti-
body levels, as well as the univariate association between drug
levels and antidrug antibody status over 12 months. Further-
more, ordinal logistic regression was used to test the associa-
tion between the EULAR response at 12 months and drug
levels. Variables that were considered to be potential con-
founders were included in the GEE models in order to obtain
adjusted estimates. To quantify the value of testing drug non-
trough levels and antidrug antibodies at 3 months as a predic-
tor of the treatment response at 12 months, the area under the
receiver operating characteristic (ROC) curve (AUC) was
used. The GEE model with a logit link for binary outcomes
was used to assess the predictors of longitudinal low-drug-
level status over time. Statistical analyses were performed
using Stata for Windows version 13.0.
RESULTS
Patient characteristics. The characteristics of the
311 patients at baseline are shown in Table 1. The majority
of patients were female; 73.0% were RF positive, and
76.4% were anti–cyclic citrullinated peptide antibody posi-
tive. All patients had active disease at baseline (mean6 SD
DAS28 5.86 0.9), and the median disease duration prior
to beginning treatment with a biologic agent was 8.1 years
(interquartile range [IQR] 3.6–16.0). At baseline, more
patients in the etanercept group were receiving hydroxy-
chloroquine (9.3% versus 2.9% of patients in the adalimu-
mab group; P5 0.02), but no other significant differences
between the 2 treatment groups were observed.
Antidrug antibodies against adalimumab, levels
of adalimumab, and association with treatment re-
sponse. Adalimumab levels and antidrug antibodies
were measured in 414 available samples obtained from
160 patients. Antidrug antibodies against adalimumab
were detected in 24.8% of patients who completed 12
months of followup (31 of 125 patients at $1 time
point) and in 19.3% of all patients in the adalimumab
group who were tested (31 of 160). The presence of
antidrug antibodies was significantly associated with
lower adalimumab levels (rs520.51, P , 0.0001; if
antidrug antibody titers were .100 AU, rs520.66,
P5 0.0041). Compared with antidrug antibody–negative
patients, those who were antidrug antibody positive had
lower mean adalimumab concentrations at 3, 6, and 12
months (see Supplementary Table 1, available on the
Arthritis & Rheumatology web site at http://onlinelibrary.
wiley.com/doi/10.1002/art.39169/abstract). The majority of
patients with antidrug antibodies (28 of 31 [90.3%]) devel-
oped immunogenicity by 6 months, and 3 other patients
developed antidrug antibodies between 6 months and 12
months. Titers of antidrug antibodies continued to
increase, for up to 12 months in some patients (median
antidrug antibody concentration 37 AU/ml [IQR 23–95]
at 3 months; 48.5 AU/ml [IQR 18–200] at 6 months; 25
AU/ml [IQR 21–2,800] at 12 months). Despite the mea-
surement of non-trough levels, the maximum antidrug
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antibody concentration detected was 111,000 AU/ml at 12
months.
There were differences at baseline between
patients in whom antidrug antibodies developed and
those in whom antidrug antibodies did not develop, par-
ticularly with regard to the median methotrexate dosage,
which was significantly higher in the latter group (Table
2). The median disease duration prior to commencing
treatment with a biologic agent was almost twice as long
in patients with antidrug antibodies compared with those
Table 1. Demographic and clinical characteristics of the patients at baseline*
Characteristic
Total patient population
(n5 331)
Adalimumab group
(n5 160)
Etanercept group
(n5 171)
Age, mean6 SD years 56.86 11 56.26 12 57.36 11
Female sex 249 (75.5) 113 (70.6) 136 (79.5)
BMI, median (IQR) kg/m2 27.5 (23.8–32.8) 27.5 (23.7–32.3) 27.5 (23.9–32.2)
Disease duration, median (IQR) years 8.1 (3.6–16.0) 8.6 (3.7–17.2) 7.8 (3.5–15.5)
RF positive† 193 (73.0) 88 (70.4) 105/139 (75.5)
Anti-CCP antibody positive† 241 (76.4) 115 (75.5) 126 (77.3)
ESR, median (IQR) mm/hour 26.0 (14.0–42.0) 28.0 (16.0–43.0) 23.5 (12.0–40.0)
CRP, median (IQR) mg/liter 11.7 (3.9–28.1) 10.5 (3.7–26.0) 12.70 (4.6–29.2)
DAS28, mean6SD 5.86 0.9 5.76 0.9 5.96 0.9
Erosive disease† 158 (65.0) 74 (64.4) 84 (65.6)
DMARD therapy
Prior biologic agent 27 (8.2) 14 (8.8) 13 (7.6)
Methotrexate 168 (50.8) 89 (55.6) 79 (46.2)
Median (IQR) mg/week 20 (15–25) 20 (15–25) 20 (15–25)
Sulfasalazine 57 (17.2) 30 (18.8) 27 (15.8)
Median (IQR) mg/day 1,000 (1,000–2,000) 1,000 (1,000–2,000) 1,000 (1,000–2,500)
Leflunomide 26 (7.9) 10 (6.3) 16 (9.4)
Hydroxychloroquine 21 (13.1) 5 (2.9) 16 (9.3)
Intramuscular gold 6 (1.9) 1 (0.6) 2 (1.1)
* The disease-modifying antirheumatic drugs (DMARDs) shown are those that were used most frequently by patients in this
cohort. Except where indicated otherwise, values are the number (%). BMI 5 body mass index; IQR 5 interquartile range;
anti-CCP 5 anti–cyclic citrullinated peptide; ESR 5 erythrocyte sedimentation rate; CRP 5 C-reactive protein; DAS28 5
Disease Activity Score in 28 joints.
† Values are the number (%) of patients with nonmissing data.
Table 2. Baseline characteristics of the patients receiving adalimumab, according to the presence or
absence of antidrug antibodies*
Characteristic
Anti-adalimumab
antibodies (n5 31)
No anti-adalimumab
antibodies (n5 129)
Age, mean6 SD years 56.06 11 56.26 12
Female sex 21 (67.7) 92 (71.3)
BMI, median (IQR) kg/m2 27.3 (24.9–32.9) 27.5 (23.5–31.6)
Disease duration, median (IQR) years 14.0 (6.7–19.4) 7.7 (3.6–16.04)
RF positive† 16 (64.0) 72 (72.0)
Anti-CCP positive† 21 (75.0) 94 (75.0)
ESR, median (IQR) mm/hour 22.5 (11.0–39) 27.5 (19.5–46.5)
CRP, median (IQR) mg/liter 9.0 (1.6–17.1) 11.2 (3.7–27.5)
DAS28, mean6SD 5.76 0.6 5.76 0.9
Erosive disease† 11 (55) 63 (66.3)
DMARD therapy
Prior biologic agent 2 (6.5) 12 (9.3)
Methotrexate 14 (45.1) 75 (58.1)
Median (IQR) mg/week 15 (10–20) 20 (15–25)
Sulfasalazine 8 (34.7) 22 (20.6)
Median (IQR) mg/day 1,000 (1,000–1,500) 1,000 (1,000–2,000)
Leflunomide 2 (6.6) 8 (6.2)
Hydroxychloroquine 0 (0) 5 (3.9)
* The disease-modifying antirheumatic drugs (DMARDs) shown are those that were used most frequently
by patients in this cohort. There were no significant differences between the groups except for disease
duration (P , 0.03) and methotrexate dosage (P , 0.012). Except where indicated otherwise, values are
the number (%). BMI5 body mass index; IQR5 interquartile range; RF5 rheumatoid factor; anti-CCP5
anti–cyclic citrullinated peptide; ESR5 erythrocyte sedimentation rate; CRP5 C-reactive protein; DAS285
Disease Activity Score in 28 joints.
† Values are the number (%) of patients with nonmissing data.
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without antidrug antibodies (14.0 years [IQR 6.7–19.4]
versus 7.7 years [IQR 3.6–16.04]; P5 0.03).
In the GEE univariate model, the adalimumab
drug level and antidrug antibody status were significantly
associated with change in the DAS28 at 12 months
(regression coefficient 0.078 [95% confidence interval
(95% CI) 0.044, 0.11], P , 0.0001 and regression coeffi-
cient 20.76 [95% CI 21.24, 20.27], P5 0.002, respec-
tively) (Table 3). The regression coefficient of 20.76
could be interpreted as the “pooled” difference in change
in the DAS28 between patients with and those without
antibodies over all followup time points, while a negative
regression coefficient value suggests an inverse relation-
ship between antidrug antibodies and improvement (i.e.,
change in the DAS28). Ordinal logistic regression further
confirmed a positive association between the EULAR
response at 12 months and the adalimumab level but a
negative relationship between the EULAR response at 12
months and antidrug antibody status (Table 3).
In the multivariable GEE model, after adjusting
for the confounders body mass index (BMI), disease
duration, age, sex, and the time-varying confounder
adherence, the relationship between the adalimumab
level and change in the DAS28 remained significant
(regression coefficient 0.060 [95% CI 0.015, 0.10], P5
0.009). A subgroup analysis was performed in the 55.6%
of patients in the methotrexate group, with adjustment
for methotrexate dose and the above variables, and the
significant association of adalimumab drug level with
change in the DAS28 was maintained (regression coeffi-
cient 0.076 [95% CI 0.028, 0.12], P5 0.002).
The concentration–effect curve for treatment
with adalimumab showed that a drug concentration of
,5 mg/ml was associated with a lower change in the
DAS28 (see Supplementary Figure 1, available on the
Arthritis & Rheumatology web site at http://onlinelibrary.
wiley.com/doi/10.1002/art.39169/abstract), similar to a
prior study using adalimumab trough levels that identi-
fied a 5–8 mg/ml therapeutic window (25). ROC curve
analysis was used to quantify the predictive value of test-
ing random drug and antidrug antibody levels at 3
months on determining an outcome of no EULAR
response at 12 months. The detection of low adalimumab
levels (,5 mg/ml) at 3 months was associated with an
AUC of 0.66 (95% CI 0.55, 0.77), and detection of anti-
drug antibodies at 3 months was associated with an AUC
of 0.68 (95% CI 0.54, 0.81). The presence of both low
adalimumab levels and antidrug antibodies at 3 months
was associated with an AUC of 0.71 (95% CI 0.57, 0.85).
In 20 samples (from 13 patients), the random mean
adalimumab drug level was ,0.1 mg/ml (0 mg/ml in 13
samples). This was significantly associated with no EULAR
response, using logistic regression (regression coefficient
2.29 [95% CI 1.13, 3.44], P , 0.0001) at the corresponding
time point. Interestingly, a good EULAR response was
observed at .1 sequential time point in 2 patients with an
adalimumab level of ,0.1 mg/ml. At 6 months and 12
months, the first patient had antidrug antibody levels of
430 AU/ml and 400 AU/ml, respectively, and the second
patient had antidrug antibody levels of 1,500 AU/ml and
9,100 AU/ml, respectively. Both patients were receiving
adalimumab monotherapy (and were not receiving metho-
trexate), suggesting that these patients may have attained
spontaneous remission and therefore no longer required
the presence of drug to achieve a good response.
Antidrug antibodies against etanercept, etaner-
cept levels, and association with treatment response. After
3, 6, and 12 months of etanercept treatment, etanercept
Table 3. Association between treatment response and adalimumab levels/antidrug antibody status*
Variable
Regression coefficient
(95% CI) P
Univariate analysis using GEE (DDAS28)
Adalimumab drug level 0.078 (0.044, 0.11) ,0.0001
Antidrug antibody status 20.76 (21.24, 20.27) 0.002
Age- and sex-adjusted model using GEE (DDAS28)
Adalimumab drug level 0.086 (0.05, 0.12) ,0.0001
Antidrug antibody status 20.80 (21.25, 20.34) 0.001
Multivariate model using GEE (DDAS28)
Adalimumab drug level 0.060 (0.015, 0.10) 0.009
Antidrug antibody status 20.22 (20.78, 20.33) 0.47
EULAR response at 12 months using ordinal logistic
regression†
Adalimumab drug level 0.11 (0.031, 0.20) 0.007
Antidrug antibody status (.12 AU/ml) 21.03 (21.99, 20.063) 0.037
* 95% CI5 95% confidence interval; GEE5 generalized estimating equation; DDAS285 change in the Disease Activ-
ity Score in 28 joints.
† All patients were categorized as having a good, moderate, or no response according to the European League Against
Rheumatism (EULAR) criteria at 12 months.
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antibodies were not detected in any of the tested patients.
Etanercept levels were measured in 421 samples from
171 patients over 12 months. The levels of etanercept
were associated with a EULAR response at 12 months in
the univariate ordinal logistic regression model (regres-
sion coefficient 0.088 [95% CI 0.019, 0.16], P5 0.012),
and this association remained significant after adjustment
for age and sex (Table 4). However, the association
between treatment response and etanercept levels lost
significance in the univariate GEE model and also in the
logistic regression model after adjusting for confounders
including age, sex, BMI, disease duration, and adherence
(Table 4). Although a trend toward higher drug levels at
12 months was shown to be associated with a good
EULAR response at 12 months (see Supplementary Fig-
ure 2, available on the Arthritis & Rheumatology web site
at http://onlinelibrary.wiley.com/doi/10.1002/art.39169/
abstract), the concentration–effect curve for etanercept did
not identify a clear therapeutic window to indicate the level
of the optimal treatment response (from concentration–
effect curves) (see Supplementary Figure 1, available on the
Arthritis & Rheumatology web site at http://onlinelibrary.
wiley.com/doi/10.1002/art.39169/abstract). Furthermore,
ROC curve analysis to quantify the value of low etaner-
cept non-trough levels (,5 mg/ml) at 3 months for pre-
dicting no EULAR response at 12 months revealed an
AUC of 0.51 (95% CI 0.41, 0.61). A lower etanercept
level cutoff of ,3.23 mg/ml (see Supplementary Figure 1,
available on the Arthritis & Rheumatology web site at
http://onlinelibrary.wiley.com/doi/10.1002/art.39169/abstract)
at 3 months resulted in an AUC of 0.58 (95% CI 0.46,
0.70), suggesting poor value of etanercept non-trough
levels for predicting no EULAR response at 12 months.
Predictors of low drug levels in patients treated
with adalimumab or etanercept. We used a GEE
model to test the longitudinal association of adalimumab
levels and antidrug antibodies over 12 months (with adali-
mumab levels as the dependent variable and antidrug
antibody status as the predictor). This demonstrated a
strong inverse association between the 2 factors (regres-
sion coefficient 24.77 [95% CI 26.39, 23.15], P ,
0.0001). To identify additional predictors of low drug lev-
els in all patients (the adalimumab and etanercept groups
combined) over 12 months and to obtain an adjusted esti-
mate of the effect of antidrug antibody status on drug
level, a logistic regression model for repeated measures
(GEE with a logit link for binary outcomes) was used.
Thresholds for low adalimumab and etanercept levels
were determined using the generated concentration–effect
curves (see Supplementary Figure 1, available on the
Arthritis & Rheumatology web site at http://onlinelibrary.
wiley.com/doi/10.1002/art.39169/abstract).
After adjustment for multiple confounders, the
strongest predictor of low drug levels over time (in
patients receiving adalimumab) continued to be anti-
drug antibody status (regression coefficient 1.27 [95%
CI 0.44, 2.07], P5 0.003). Self-reported adherence data
Table 4. Association of the treatment response with etanercept levels*
Regression coefficient
(95% CI) P
Univariate analysis using GEE
Etanercept level 0.0080 (20.51, 0.031) 0.51
EULAR response at 12 months using ordinal logistic
regression (univariate analysis)
Etanercept level 0.088 (0.019, 0.16) 0.012
EULAR response at 12 months, age- and sex-adjusted,
using ordinal logistic regression
Etanercept level 0.081 (0.011, 0.15) 0.022
EULAR response at 12 months multivariate-adjusted
model, using ordinal logistic regression†
Etanercept level 0.057 (20.050, 0.16) 0.30
* All patients were categorized as having a good, moderate, or no response according to the European
League Against Rheumatism (EULAR) criteria. 95% CI5 95% confidence interval; GEE5 generalized
estimating equation.
† Adjusted for age, sex, body mass index, disease duration, and adherence.
Table 5. Predictors of low drug levels in adalimumab- and etanercept-
treated patients, using GEE for binary outcomes*
Variable Coefficient (95% CI) P
Age 0.0056 (20.20, 20.031) 0.67
Sex 0.054 (20.58, 20.69) 0.87
Body mass index 0.055 (0.017, 0.094) 0.005
Baseline disease activity† 0.15 (20.21, 20.50) 0.43
Methotrexate use 20.15 (20.67, 0.38) 0.59
Antidrug antibody status‡ 1.27 (0.44, 2.07) 0.003
Adherence 20.68 (21.29, 20.07) 0.028
* A low adalimumab level was defined as ,5 mg/ml, and a low eta-
nercept level was defined as ,3.62 mg/ml. GEE5 generalized esti-
mating equation; 95% CI5 95% confidence interval.
† Based on the Disease Activity Score in 28 joints.
‡ Adalimumab-treated patients only.
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were available for 80.4% of adalimumab-treated patients
and 73.1% of etanercept-treated patients at all time
points over 12 months. Adherence and BMI were also
shown to be significant predictors in the fully adjusted
model (Table 5). In the combined GEE model including
adalimumab and etanercept, a BMI of $30 kg/m2 was
associated with low drug levels (regression coefficient
0.78 [95% CI 0.37, 1.18], P , 0.0001).
DISCUSSION
Our study is the first to demonstrate that adalimu-
mab drug levels and antidrug antibody status, ascertained
from non–trough-level serum samples, are useful for the
early prediction of a EULAR response at 12 months. Of
the 2 variables, the adalimumab drug level was the better
predictor of treatment response, after adjustment for con-
founding variables. Etanercept drug levels, tested in non–
trough-level serum samples, had a wider variation over 12
months of treatment and were less useful as a predictor of
the future treatment response. BMI and adherence
appeared to be significant predictors of drug levels in both
adalimumab- and etanercept-treated patients.
The main strengths of the study include a large
sample size, prospective serial sampling, a well-characterized
cohort of patients, and availability of other outcome
measures such as self-reported adherence. Because
serum samples were obtained during routine clinic vis-
its, as opposed to trough serum samples, a pragmatic
approach to immunogenicity/drug level testing can be
evaluated because, in a clinical setting, it may not always
be possible to obtain serum just before the patient is
due to receive the next injection. We chose to test for
immunogenicity using RIA, because this method is less
prone to drug interference than the more commonly
used bridging ELISA method. However, in the presence
of circulating drug levels, RIA may still be prone to
drug interference, and it should be noted that in our
study antidrug antibodies to adalimumab were detected
in a lower number of RA patients compared with previ-
ous estimates using the same assay (5). In the future,
newer techniques, such as pH-shift–anti-idiotype anti-
gen-binding tests (pH dissociation assays that are based on
acid dissociation of adalimumab–antidrug antibody com-
plexes and therefore are more sensitive in the presence of
free drug), may be more useful in this setting (20).
The results of the current study are consistent
with those of several previous studies that confirmed
that treatment failure is higher in patients in whom
antidrug antibodies to monoclonal antibodies such as
adalimumab and infliximab develop (6,26). The under-
lying mechanism is thought to be either increased drug
clearance or neutralization of the active component of
the protein (27,28). It appears that the effect of anti-
drug antibodies on the drug level is of the most clinical
significance. We showed an inverse correlation be-
tween antidrug antibodies and drug levels, suggesting
that measurement of antidrug antibodies may be useful
to determine the etiology of low adalimumab non-
trough levels, therefore facilitating the decision regard-
ing the next therapeutic option in nonresponding
patients, similar to previously published algorithms
(29,30). In keeping with a previous study, median
methotrexate doses were lower in patients in whom
immunogenicity developed compared with patients in
whom immunogenicity did not develop (31). This sug-
gests that both continued treatment with methotrexate
and anti-TNF therapy (11) as well as administration of
methotrexate at the maximum tolerated dose may be
important in preventing immunogenicity and future
loss of response.
Previous studies using RIAs and ELISAs also
failed to detect antidrug antibodies to etanercept
(23,24,32), and in those studies in which these antibod-
ies were observed, antidrug antibodies had no apparent
effect on treatment response or clinical outcome
(33–35). Low trough concentrations of etanercept have
previously been associated with a poor response to
treatment in patients with RA treated with etanercept
for up to 6 months (23). In our study, etanercept levels
were associated with a EULAR response at 12 months
(by univariate analysis only); however, there was not a
clear cutoff to identify a therapeutic concentration
range. A similar wide variation in the concentration–
effect curve was also seen recently in an ankylosing
spondylitis cohort study that measured etanercept
trough levels (36). This variability may be attributable to
the short half-life of etanercept (100 hours), suggesting
that pre-dose sampling is particularly important when
interpreting the results for this drug.
Several extrinsic and intrinsic factors may also
influence the pharmacokinetics of anti-TNF agents,
such as BMI (higher weight is associated with a larger
central volume of distribution), sex (which affects vol-
ume/distribution, with shorter half-lives in female
patients) (37), adherence, disease activity, and albumin
levels (high disease activity and low albumin levels are
associated with accelerated drug clearance). A major
strength of the current study design was that each of
these factors (except albumin) was recorded for our
patients, but the association with drug levels remained
significant even after adjustment for these confounders
in adalimumab-treated patients.
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In a clinical setting, testing for adalimumab levels
could inform practice. In the absence of antidrug anti-
bodies, a low drug level may be attributable to a high
BMI and therefore volume of distribution. BMI has been
described as a factor affecting anti-TNF levels (23,36);
however, previously reported data have been inconclu-
sive. A BMI cutoff of $30 kg/m2 in our patients was
determined as being significant enough to be associated
with lower drug levels in both the adalimumab and eta-
nercept cohorts. Patients with high BMIs may fail to
respond not only due to issues of bioavailability/volume
of distribution leading to a lower drug level, but also due
to the inflammatory effect of adipose tissue influencing
the target load (38). Using an anti-TNF agent that
accounts for patient weight (e.g., switching to an intrave-
nous alternative) or escalating the dose of subcutaneous
therapy may be a more effective strategy in patients with
a high BMI; however, this notion needs to be fully
explored in a randomized controlled trial.
In patients with a low drug level, a normal BMI,
and no antidrug antibodies, the clinician may prompt a
discussion with the patient regarding adherence to the
medication; we observed that poor adherence or non-
adherence was a predictor of low non-trough levels
and also has previously been associated with a poor
treatment response (18). Furthermore, 2 patients in our
study achieved a good EULAR response at 6 months
and 12 months, in the presence of undetectable adali-
mumab levels in association with high-titer antidrug
antibodies. This would suggest that their disease had
entered spontaneous remission, obviating the need for
continuation of treatment with an anti-TNF agent.
Therefore, this situation represents a unique opportu-
nity for stopping treatment with these expensive drugs
in such responding patients.
In conclusion, in the context of drug non-trough
levels, measurement of adalimumab levels and antidrug
antibodies early in the treatment course is predictive of
subsequent treatment response. Consideration of these
factors, along with BMI and adherence, may help when
deciding the best treatment strategy in patients in whom
adalimumab does not appear to be effective. To maxi-
mize the chances of efficacy, methotrexate treatment
should be maintained at the highest dose the patient
can tolerate. Etanercept non-trough levels, while associ-
ated with treatment response, were less predictive and
unlikely to be clinically useful in isolation.
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